

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/1-FO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	1	of	1	Attorney Docket Number	1694.0580004/JMC/CMB

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
	FP1	WO 92/11012 A1	07/09/1992	Schering Aktiengesellschaft Berlin und Bergkamen		Abs
	FP2	WO 01/82926 A1	11/08/2001	Lampidis <i>et al.</i>		
	FP3	WO 03/099285 A1	12/04/2003	The Hospital for Sick Children; Pace-Asciak		
	FP4	WO 2004/062614 A2	07/29/2004	New River Pharmaceuticals Inc.; Mickle <i>et al.</i>		


684996 1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	1	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	ABRAHA, A., <i>et al.</i> , "Inhibition of Tumor Cell Proliferation by Dexamethasone: ³¹ P NMR Studies of RIF-1 Fibrosarcoma cells Perfused <i>in vitro</i> ," <i>NMR in Biomedicine</i> 9:173-178, Wiley-Liss, Inc. (1996)	
	NPL2	ACHILEFU, S., <i>et al.</i> , "Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging," <i>Invest. Radiol.</i> 35:479-485, Lippincott Williams & Wilkins, Inc. (2000)	
	NPL3	ACHILEFU, S., <i>et al.</i> , "Synthesis, In Vitro Receptor Binding, and In Vivo Evaluation of Fluorescein and Carbocyanine Peptide-Based Optical Contrast Agents," <i>J. Med. Chem.</i> 45:2003-2015, American Chemical Society (May 2002)	
	NPL4	AIKEN, N.R., <i>et al.</i> , " ³¹ P NMR Spectroscopic Studies of the Effects of Cyclophosphamide on Perfused RIF-1 Tumor Cells," <i>Magn. Reson. Med.</i> 31:241-247, Williams & Wilkins (1994)	
	NPL5	ALAVI, A., and Reivich, M., "Guest Editorial: The Conception of FDG-PET Imaging," <i>Semin. Nucl. Med.</i> 32:2-5, W.B. Saunders Company (January 2002)	
	NPL6	BAIDOO, K. E., Mathews, W., and Wagner, H. N., Fluorescent imaging of deoxyglucose. 8th Intl. Conf: Peace through Mind/Brain Science Hamamatsu, Japan, February 2-4, 2000	
	NPL7	BECKER, A., <i>et al.</i> , "Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands," <i>Nature Biotechnol.</i> 19:327-331, Nature America, Inc. (2001)	
	NPL8	BENARON, D.A., <i>et al.</i> , "Enabling Molecular Imaging in the Operating Room: the Palomar TM Real-Time Room-Light Molecular Imaging System," <i>Molecular Imaging</i> 2:S194, MIT Press (July 2003)	
	NPL9	BERKOWITZ, B.A. and Ackerman, J.J.H., "Proton Decoupled Fluorine Nuclear Magnetic Resonance Spectroscopy In Situ," <i>Biophys. J.</i> 51:681-685, Biophysical Society (1987)	
	NPL10	BHUJWALLA, Z.M., <i>et al.</i> , "Energy Metabolism, pH Changes, and Lactate Production in RIF-1 Tumors Following Intratumoral Injection of Glucose," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 22:95-101, Pergamon Press (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	2	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	BHUIWALLA, Z.M., <i>et al.</i> , "Glucose Metabolism in RIF-1 Tumors after Reduction in Blood Flow: An <i>In Vivo</i> ¹³ C and ³¹ P NMR Study," <i>Magn. Reson. Med.</i> 32:303-309, Williams & Wilkins (1994)	
	NPL12	BINDER C. <i>et al.</i> , "Deregulated Simultaneous Expression of Multiple Glucose Transporter Isoforms in Malignant Cells and Tissues," <i>Anticancer Res.</i> 17:4299-4304, J.G. Delinassios (1997)	
	NPL13	BLOKLAND, J.A., <i>et al.</i> , "Positron emission tomography: a technical introduction for clinicians," <i>Eur. J. Radiol.</i> 44:70-75, Elsevier Science Ireland Ltd. (October 2002)	
	NPL14	BRAUNSCHWEIGER, P.G., <i>et al.</i> , "Potentiation of Interleukin 1 α Mediated Antitumor Effects by Ketoconazole," <i>Cancer Res.</i> 50:4709-4717, American Association for Cancer Research (1990)	
	NPL15	BRIASOULIS, E., <i>et al.</i> , "Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group," <i>J. Clin. Oncol.</i> 18:3535-3544, American Society of Clinical Oncology (2000)	
	NPL16	BUGAJ, J.E., <i>et al.</i> , "Novel fluorescent contrast agents for optical imaging of <i>in vivo</i> tumors based on a receptor-targeted dye-peptide conjugate platform," <i>J. Biomed. Opt.</i> 6:122-133, SPIE (2001)	
	NPL17	CHANCE, B., <i>et al.</i> , "Oxidation-Reduction Ratio Studies of Mitochondria in Freeze-trapped Samples," <i>J. Biol. Chem.</i> 254:4764-4771, American Society for Biochemistry and Molecular Biology (1979)	
	NPL18	CHANCE, B., <i>et al.</i> , "Highly sensitive object location in tissue models with linear in-phase and anti-phase multi-element optical arrays in one and two dimensions," <i>Proc. Natl. Acad. Sci. USA</i> 90:3423-3427, National Academy of Sciences (1993)	
	NPL19	CHANCE, B., <i>et al.</i> , "Precision localization of hidden absorbers in body tissues with phased-array optical systems," <i>Rev. Sci. Instrum.</i> 67:4324-4332, American Institute Of Physics (1996)	
	NPL20	CHANG, C.H.F., <i>et al.</i> , "The Interactions of Gallium with Various Buffers and Chelating Agents in Aqueous Solution: Gallium-71 and Hydrogen-1 NMR Studies," <i>Bioinorg. Chem.</i> 8:11-19, Elsevier North-Holland, Inc. (1978)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	3	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	CHEN, Y., <i>et al.</i> , "Bacteriopurpurinimides: Highly Stable and Potent Photosensitizers for Photodynamic Therapy," <i>J. Med. Chem.</i> 45:255-258, American Chemical Society (January 2002)	
	NPL22	CHEN, Y., <i>et al.</i> , "Near-infrared phase cancellation instrument for fast and accurate localization of fluorescent heterogeneity," <i>Rev. Sci. Instrum.</i> 74:3466-3473, American Institute of Physics (July 2003)	
	NPL23	CHEN, Y., <i>et al.</i> , "Metabolism-enhanced tumor localization by fluorescence imaging: <i>in vivo</i> animal studies," <i>Optics Lett.</i> 28:2070-2072, Optical Society of America (November 2003)	
	NPL24	COHADE, C., and Wahl, R.L., "PET Scanning and Measuring the Impact of Treatment," <i>Cancer J.</i> 8:119-134, Jones and Bartlett Publishers, Inc. (March/April 2002)	
	NPL25	COLVIN, M. and Hilton, J., "Pharmacology of Cyclophosphamid and Metabolites," <i>Cancer Treat. Rep.</i> 65:89-95, U.S. National Cancer Institute (1981)	
	NPL26	COLVIN, M., "The Comparative Pharmacology of Cyclophosphamide and Ifosphamide," <i>Semin. Oncol.</i> 9:2-7, Grune & Stratton, Inc. (1981)	
	NPL27	COLVIN, O.M., "An Overview of Cyclophosphamide Development and Clinical Applications," <i>Curr. Pharm. Design</i> 5:555-560, Bentham Science Publishers B.V. (1999)	
	NPL28	COLVIN, O.M., <i>et al.</i> , "Role of Glutathione in Cellular Resistance to Alkylating Agents," <i>Adv. Enzyme Regul.</i> 33:19-26, Pergamon Press Ltd. (1993)	
	NPL29	CZERNIN, J., "Clinical Applications of FDG-PET in Oncology," <i>Acta Medica Austriaca</i> 29:162-170, Blackwell Publishing Ltd. (November 2002)	
	NPL30	CZEMIN, J. and Phelps, M.E., "Positron Emission Tomography Scanning: Current and Future Applications," <i>Ann. Rev. Med.</i> 53:89-112, Annual Reviews (February 2002)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	4	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	DEUEL, R.K., et al., "Monitoring the Time Course of Cerebral Deoxyglucose Metabolism by ³¹ P Nuclear Magnetic Resonance Spectroscopy," <i>Science</i> 228:1329-1331, American Association for the Advancement of Science (1985)	
	NPL32	DOUGHERTY, T.J., et al., "Photodynamic Therapy," <i>J. Natl. Cancer Inst.</i> 90:889-905, Oxford University Press (1998)	
	NPL33	DUVVURI, U., et al., "Quantitative T ₁ ρ magnetic Resonance Imaging of RIF-1 Tumors in Vivo: Detection of Early Response to Cyclophosphamide Therapy," <i>Cancer Res.</i> 61:7747-7753, American Association for Cancer Research (2001)	
	NPL34	FIEDOR, J., et al., "Photodynamics of the Bacteriochlorophyll-Carotenoid System. 2. Influence of Central Metal, Solvent and β-Carotene on Photobleaching of Bacteriochlorophyll Derivatives," <i>Photochem. Photobiol.</i> 76:145-152, American Society for Photobiology (August 2002)	
	NPL35	FISHKIN, J.B., and Gratton, E., "Propagation of photon-density waves in strongly scattering media containing an absorbing semi-infinite plane bounded by a straight edge," <i>J. Opt. Soc. Am.</i> 10:127-140, Optical Society of America (1993)	
	NPL36	FLANAGAN, Jr., J.H., et al., "Functionalized Tricarbocyanine Dyes as Near-Infrared Fluorescent Probes for Biomolecules," <i>Bioconj. Chem.</i> 8:751-756, American Chemical Society (1997)	
	NPL37	FLIER, J.S., et al., "Elevated Levels of Glucose Transport and Transporter Messenger RNA are Induced by <i>ras</i> or <i>src</i> Oncogenes," <i>Science</i> 235:1492-1495, American Association for the Advancement of Science (1987)	
	NPL38	FOLLI, S., et al., "Antibody-Indocyanin Conjugates for Immunophotodetection of Human Squamous Cell Carcinoma in Nude Mice," <i>Cancer Res.</i> 54:2643-2649, American Association for Cancer Research (1994)	
	NPL39	FRIEDMAN, H.S., et al., "Glutathione Protects Cardiac and Skeletal Muscle from Cyclophosphamide-induced Toxicity," <i>Cancer Res.</i> 50:2455-2462, American Association for Cancer Research (1990)	
	NPL40	FRIEDMAN, H.S., et al., "O ⁶ -Benzylguanine-mediated Enhancement of Chemotherapy," <i>Mol. Cancer Thera.</i> 1:943-948, American Association for Cancer Research, Inc. (September 2002)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	5	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	FUNG, L.K., <i>et al.</i> , "Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer Implant in the Monkey Brain," <i>Cancer Res.</i> 58:672-684, American Association for Cancer Research (1998)	
	NPL42	GAMBHIR, S.S., "Molecular Imaging of Cancer with Positron Emission Tomography," <i>Nature Rev. Cancer</i> 2:683-693, Nature Publishing Group (September 2002)	
	NPL43	GAMS, R.A., <i>et al.</i> , "Serum Inhibition of <i>in Vitro</i> ⁶⁷ Ga Binding by L1210 Leukemic Cells," <i>Cancer Res.</i> 35:1422-1426, American Association for Cancer Research (1975)	
	NPL44	GAMS, R.A., <i>et al.</i> , "Effect of Growth Rate and Simian Adenovirus-7 Transformation on <i>in vitro</i> ⁶⁷ Ga Binding to Hamster Embryo Cells," <i>J. Nucl. Med.</i> 16:231-233, Society of Nuclear Medicine (1975)	
	NPL45	GIORGETTI, A., <i>et al.</i> , "Clinical oncological Applications of Positron Emission Tomography (PET) using Fluorine-18-Fluoro-2-deoxy-D-glucose," <i>Radiol. Med.</i> 103:293-318, Springer Milan (April 2002)	
	NPL46	GLICKSON, J.D., <i>et al.</i> , " <i>In Vitro</i> Binding of ⁶⁷ Ga to L1210 cells," <i>Cancer Res.</i> 33:2706-2713, American Association for Cancer Research (1973)	
	NPL47	GU, Y.Q., <i>et al.</i> , "High-resolution three-dimensional scanning optical image system for intrinsic and extrinsic contrast agents in tissue," <i>Rev. Sci. Instrum.</i> 73:172-178, American Institute of Physics (January 2002)	
	NPL48	GURFINKEL, M., <i>et al.</i> , "Pharmacokinetics of ICG and HPPH-car for the Detection of Normal and Tumor Tissue using Fluorescence, Near-infrared Reflectance Imaging: A Case Study," <i>Photochem. Photobiol.</i> 72:94-102, American Society for Photobiology (2000)	
	NPL49	HAMBURGER, A.W., and Salmon, S.E., "Primary Bioassay of Human Tumor Stem Cells," <i>Science</i> 197:461-463, American Association for the Advancement of Science (1977)	
	NPL50	HARRIS, D.S., <i>et al.</i> , "Polarized distribution of glucose transporter isoforms in Caco-2 cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:7556-7560, National Academy of Sciences (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	6	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL51	HARTWICH, G., <i>et al.</i> , "Metal-Substituted Bacteriochlorophylls. 1. Preparation and Influence of Metal and Coordination on Spectra," <i>J. Am. Chem. Soc.</i> 120:3675-3683, American Chemical Society (1998)	
	NPL52	Helliwell, P.A., and Kellett, G.L., "The active and passive components of glucose absorption in rat jejunum under low and high perfusion stress," <i>J. Physiol.</i> 544:579-589, The Physiological Society (October 2002)	
	NPL53	HENDERSON, B.W., <i>et al.</i> , "An <i>in Vivo</i> Quantitative Structure-Activity Relationship for a Congeneric Series of Pyropheophorbide Derivatives as Photosensitizers for Photodynamic Therapy," <i>Cancer Res.</i> 57:4000-4007, American Association for Cancer Research (1997)	
	NPL54	HUSTINX, R., <i>et al.</i> , Whole-Body FDG-PET Imaging in the Management of Patients With Cancer," <i>Semin. Nucl. Med.</i> 32:35-46, W.B. Saunders Company (January 2002)	
	NPL55	INOUE, T., <i>et al.</i> , "A shifting landscape: What will be next FDG in PET oncology?" <i>Ann. Nucl. Med.</i> 16:1-9, Japanese Society of Nuclear Medicine (February 2002)	
	NPL56	INTES, X., <i>et al.</i> , "Detection limit enhancement of fluorescent heterogeneities in turbid media by dual-interfering excitation," <i>Appl. Opt.</i> 41:3999-4007, Optical Society of America (July 2002)	
	NPL57	ISHIKAWA N, <i>et al.</i> , "SGLT Gene Expression in Primary Lung Cancers and Their Metastatic Lesions," <i>Jpn. J. Cancer Res.</i> 92:874-879, Japanese Cancer Association (2001)	
	NPL58	JAHDE, E., <i>et al.</i> , "Hydrogen Ion-Mediated Enhancement of Cytotoxicity of Bis-Chloroethylating Drugs in Rat Mammary Carcinoma Cells <i>in Vitro</i> ," <i>Cancer Res.</i> 49:2965-2972, American Association for Cancer Research (1989)	
	NPL59	JAHDE, E., <i>et al.</i> , "pH in Human Tumor Xenografts and Transplanted Rat Tumors: Effect of Insulin, Inorganic Phosphate, and <i>m</i> -Iodobenzylguanidine," <i>Cancer Res.</i> 52:6209-6215, American Association for Cancer Research (1992)	
	NPL60	JERUSALEM, G., <i>et al.</i> , "The value of positron emission tomography (PET) imaging in disease staging and therapy assessment," <i>Ann. Oncol.</i> 13:227-234, European Society for Medical Oncology (October 2002)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	7	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL61	KAIZER, H., <i>et al.</i> , "Autologous Bone Marrow Transplantation in Acute Leukemia and Non-Hodgkin's Lymphoma: A Phase I Study of 4-Hydroperoxycyclophosphamide (4HC) Incubation of Marrow Prior to Cryopreservation," <i>Haematol. Blood Transfus.</i> 28:90-101, Springer-Verlag (1983)	
	NPL62	KAPLAN, O., <i>et al.</i> , "Effects of 2-Deoxyglucose on Drug-sensitive and Drug-Resistant Human Breast Cancer Cells: Toxicity and Magnetic Resonance Spectroscopy Studies of Metabolism," <i>Cancer Res.</i> 3:544-551, American Association for Cancer Research (1990)	
	NPL63	KOTYK, J.J., <i>et al.</i> , "Simultaneous In Vivo Monitoring of Cerebral Deoxyglucose and Deoxyglucose-6-Phosphate by ¹³ C{1H} Nuclear Magnetic Resonances Spectroscopy," <i>J. Neurochem.</i> 53:1620-1628, Raven Press, Ltd. (1989)	
	NPL64	KOZYREV, A.N., <i>et al.</i> , "Syntheses of Stable Bacteriochlorophyll-a Derivatives as Potential Photosensitizers for Photodynamic Therapy," <i>Tetrahedron Lett.</i> 37:6431-6434, Elsevier Science Ltd. (1996)	
	NPL65	KUIN, A., <i>et al.</i> , "Reduction of Intratumoral pH by the Mitochondrial Inhibitor <i>m</i> -Iodobenzylguanidine and Moderate Hyperglycemia," <i>Cancer Res.</i> 54:3785-3792, American Association for Cancer Research (1994)	
	NPL66	KUIN, A., <i>et al.</i> , "Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor <i>m</i> -iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)," <i>Br. J. Cancer</i> 79:793-801, Nature Publishing Group (1999)	
	NPL67	LEPPENS-LUISIER, G., <i>et al.</i> , "Facilitated glucose transporters play a crucial role throughout mouse preimplantation embryo development," <i>Hum. Reprod.</i> 16:1229-1236, European Society of Human Reproduction and Embryology (2001)	
	NPL68	LI, H., <i>et al.</i> , NIR Optical Probes Targeting Glucose Transporters, SPIE Photonic West Meeting, January 27, 2004	
	NPL69	LI, S.-J., <i>et al.</i> , Response of Radiation-induced Fibrosarcoma-1 in Mice to Cyclophosphamide Monitored by <i>in Vivo</i> ³¹ P Nuclear Magnetic Resonance Spectroscopy," <i>Cancer Res.</i> 48:4736-4742, American Association for Cancer Research (1988)	
	NPL70	LICHA, K., "Contrast Agents for Optical Imaging," <i>Top. Curr. Chem.</i> 222:1-29, Springer-Verlag (September 2002)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	8	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL71	LIU, H., et al., "Hypersensitization of Tumor Cells to Glycolytic Inhibitors," <i>Biochemistry</i> 40:5542-5547, American Chemical Society (2001)	
	NPL72	LIU, H., et al., "Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C)," <i>Biochem. Pharmacol.</i> 64:1746-1751, Elsevier Science Inc. (December 2002)	
	NPL73	LIN, Y., et al., "Novel Near-Infrared Cyanine Fluorochromes: Synthesis, Properties, and Bioconjugation," <i>Bioconjugate Chem.</i> 13:605-610, American Chemical Society (May-June 2002)	
	NPL74	LLOYD, P.G., et al., "Examining Glucose Transport in Single Vascular Smooth Muscle Cells with a Fluorescent Glucose Analog," <i>Physiol. Res.</i> 48:401-410, The Institute of Physiology of The Czechoslovak Academy of Sciences (1999)	
	NPL75	LUDEMAN, S.M., "The Chemistry of the Metabolites of Cyclophosphamide," <i>Curr. Pharm. Design</i> 5:627-643, Bentham Science Publishers B.V. (1999)	
	NPL76	MAISEY, M.N., "Overview of clinical PET," <i>Br. J. Radiol.</i> 75:S1-S5, British Institute of Radiology (November 2002)	
	NPL77	MASCHEK, G., et al., "2-Deoxy-D-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers <i>In Vivo</i> ," <i>Cancer Res.</i> 64:31-34, American Association for Cancer Research (January 2004)	
	NPL78	MEDINA, R.A. and Owen, G.I., "Glucose transporters: expression, regulation and cancer," <i>Biol. Res.</i> 35:9-26, Society of Biology of Chile (April 2002)	
	NPL79	MOON, W.K., et al., "Enhanced Tumor Detection Using a Folate Receptor-Targeted Near-Infrared Fluorochrome Conjugate," <i>Bioconjug. Chem.</i> 14:539-545, American Chemical Society (May-June 2003)	
	NPL80	MOREB, J., et al., "Role of Sldehyde Dehydrogenase in the Protection of Hematopoietic Progenitor Cells from 4-Hydroperoxycyclophosphamide by interleukin 1 β and Tumor Necrosis Factor," <i>Cancer Res.</i> 52:1770-1774, American Association for Cancer Research (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	9	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL81	MUJUMDAR, S.R., <i>et al.</i> , "Cyanine-Labeling Reagents: Sulfo benzindocyanine Succinimidyl Esters," <i>Bioconjugate Chem.</i> 7:356-362, American Chemical Society (1996)	
	NPL82	NATARAJAN, A., and Srienc, F., "Glucose uptake rates of single <i>E. coli</i> cells grown in glucose-limited chemostat cultures," <i>J. Microbiol. Methods</i> 42:87-96, Elsevier Science B.V. (2000)	
	NPL83	OH, K.-B. and Matsuoka, H., "Rapid viability assessment of yeast cells using vital staining with 2-NBDG, a fluorescent derivative of glucose," <i>Int. J. Food Microbiol.</i> 76:47-53, Elsevier Science B.V. (June 2002)	
	NPL84	PANDEY, R.K. and Zheng, G., "Porphyrins as Photosensitizers in Photodynamic Therapy," in <i>The Porphyrins handbook</i> , Kadish, K.M., <i>et al.</i> , eds., Academic Press, Boston, MA, pp. 157-230 (2000)	
	NPL85	PARK, K.-H., <i>et al.</i> , "Probe of specific interaction between a simplified synthetic glycopolymer and erythrocytes as mediated by a glucose transporter (GLUT) on a cell membrane," <i>J. Biomed. Mater. Res.</i> 59:591-594, John Wiley & Sons, Inc. (March 2002)	
	NPL86	PATTERSON, M.S., <i>et al.</i> , "Time resolved reflectance and transmittance for the non-invasive measurement of tissue optical properties," <i>Appl. Opt.</i> 28:2331-2336, Optical Society of America (1989)	
	NPL87	PAUWELS, E.K.J., <i>et al.</i> , "FDG Accumulation and Tumor Biology," <i>Nucl. Med. Biol.</i> 25:317-322, Elsevier Science Inc. (1998)	
	NPL88	QUISTORFF, B., <i>et al.</i> , "High Spatial Resolution Readout 3-D /metabolic Organ Structure: An Automated, Low-Temperature Redox Ratio-Scanning Instrument," <i>Anal. Biochem.</i> 148:389-400, Academic Press (1985)	
	NPL89	RAJAN, S.S., <i>et al.</i> , " ³¹ P NMR Spectroscopic Study of Bioenergetic Changes in Radiation-induced Fibrosarcoma-1 After Radiation Therapy," <i>NMR in Biomedicine</i> 2:165-171, Hayden & Son Limited (1989)	
	NPL90	RAMANUJAM, N., <i>et al.</i> , "Low temperature fluorescence imaging of freeze-trapped human cervical tissues," <i>Opt. Express</i> 8:335-343, Optical Society of America (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	10	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL91	ROMÁN, Y., <i>et al.</i> , "Confocal microscopy study of the different patterns of 2-NBDG uptake in rabbit enterocytes in the apical and basal zone," <i>Pflügers Arch.-Eur. J. Physiol.</i> 443:234-239, Springer-Verlag (2001)	
	NPL92	ROSENBACH-BELKIN, V., <i>et al.</i> , "Serine Conjugates of Chlorophyll and Bacteriochlorophyll: Photocytotoxicity <i>in vitro</i> and Tissue Distribution in Mice Bearing Melanoma Tumors," <i>Photochem. Photobiol.</i> 64:174-181, American Society for Photobiology (1996)	
	NPL93	RUSSO, J.E., <i>et al.</i> , "The Role of Aldehyde Dehydrogenase Isozymes in Cellular Resistance to the Alkylating Agent Cyclophosphamide," <i>Enzymol. Mol. Biol. Carbonyl. Metabol.</i> 2:65-79, Alan R. Liss, Inc. (1989)	
	NPL94	SCHIFFER, L.M., and Braunschweiger, P.G., "Preliminary Observations on the Correlation of Proliferative Phenomena with <i>in Vivo</i> ³¹ P NMR Spectroscopy after Tumor Chemotherapy," <i>Ann. N.Y. Acad. Sci.</i> 459:270-277, New York Academy of Sciences (1985)	
	NPL95	SCHREIBER, S., <i>et al.</i> , "Local Photodynamic Therapy (PDT) of Rat C6 Glioma Xenografts with Pd-Bacteriopheophorbide Leads to Decreased Metastases and Increase of Animal Cure Compared with Surgery," <i>Int. J. Cancer</i> 99:279-285, Wiley-Liss, Inc. (May 2002)	
	NPL96	SCHWAIGER, M., "Functional imaging for assessment of therapy," <i>Br. J. Radiol.</i> 75:S67-S73, British Institute of Radiology (November 2002)	
	NPL97	SEMENZA, G.L., and Wang, G.L., "A Nuclear Factor Induced by Hypoxia via De Novo Protein Synthesis Binds to the Human Erythropoietin Gene Enhancer at a Site Required for Transcriptional Activation," <i>Mol. Cell. Biol.</i> 12:5447-5454, American Society for Microbiology (1992)	
	NPL98	SPEIZER, L., <i>et al.</i> , "Asymmetric transport of a fluorescent glucose analogue by human erythrocytes," <i>Biochim. Biophys. Acta</i> 815:75-84, Elsevier Science Publishers B.V. (1985)	
	NPL99	STERNBERG, E.D., and Dolphin, D., "Porphyrin-based Photosensitizers for Use in Photodynamic Therapy," <i>Tetrahedron</i> 54:4151-4202, Elsevier Science Ltd. (1998)	
	NPL100	STÜBEN, J., <i>et al.</i> , "Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent β-D-glucosylisophosphoramidate mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat," <i>Cancer Chemother. Pharmacol.</i> 38:355-365, Springer-Verlag (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	11	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL101	TEERIJOKI, H., <i>et al.</i> , "Monosaccharide uptake in common carp (<i>Cyprinus carpio</i>) EPC cells is mediated by a facilitative glucose carrier," <i>Comp. Biochem. Physiol. Part B</i> 128:483-491, Elsevier Science Inc. (2001)	
	NPL102	TURKINGTON, T.G. and Coleman, R.E., "Clinical Oncologic Positron Emission Tomography: An Introduction," <i>Seminars in Roentgenology</i> 37:102-109, Elsevier Science (April 2002)	
	NPL103	TWENTYMAN, P.R., <i>et al.</i> , "A New Mouse Tumor System (RIF-1) for Comparison of End-Point Studies," <i>J. Natl. Cancer Inst.</i> 49:595-604, Oxford University Press (1980)	
	NPL104	VAN DE WIELE, C., <i>et al.</i> , "Nuclear Medicine Imaging to Predict Response to Radiotherapy: A Review," <i>Int. J. Rad. Oncol. Biol. Phys.</i> 55:5-15, Elsevier Science Inc. (January 2003)	
	NPL105	VAUPEL, P., <i>et al.</i> , "Blood Flow, Oxygen and Nutrient Supply, and Metabolic Microenvironment of Human Tumors: A Review," <i>Cancer Res.</i> 49:6449-6465, American Association for Cancer Research (1989)	
	NPL106	VEYHL, M., <i>et al.</i> , "Transport of the new chemotherapeutic agent β -D-glucosylisophosphoramidate mustard (D-19575) into tumor cells is mediated by the Na ⁺ -D-glucose cotransporter SAAT1," <i>Proc. Natl. Acad. Sci. USA</i> 95:2914-2919, National Academy of Sciences (1998)	
	NPL107	WARBURG, Otto (Ed.), "The Metabolism of Tumours," Constable & Co., Ltd., London (1930)	
	NPL108	WEHRLE, J.P., <i>et al.</i> , " ³¹ P and ¹ H NMR Spectroscopy of Tumors <i>in Vivo</i> : Untreated Growth and Response to Chemotherapy," <i>Ann. N.Y. Acad. Sci.</i> 508:200-215, New York Academy of Sciences (1987)	
	NPL109	WEINHOUSE, S., "The Warburg Hypothesis Fifty Years Later," <i>Cancer Res. Clin. Oncol.</i> 87:115-126, Springer-Verlag (1976)	
	NPL110	WEISHAUPT, K.R., <i>et al.</i> , "Identification of Singlet Oxygen as the Cytotoxic Agent in Photo-Inactivation of a Murine Tumor," <i>Cancer Res.</i> 36:2326-2329, American Association for Cancer Research (1976)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	12	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²	
	NPL111	WEISSLEDER, R., <i>et al.</i> , "In vivo imaging of tumors with protease-activated near-infrared fluorescent probes," <i>Nature Biotechnol.</i> 17:375-378, Nature America Inc. (1999)		
	NPL112	WEISSLEDER, R., and Mahmood, U., "Molecular Imaging," <i>Radiology</i> 219:316-333, Radiological Society of North America (2001)		
	NPL113	WEISSLEDER, R., and Ntziachristos, V., "Shedding light onto live molecular targets," <i>Nature Med.</i> 9:123-128, Nature Publishing Company (January 2003)		
	NPL114	WOOD, I.S., and Trayhurn, P., "Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins," <i>Br. J. Nutr.</i> 89:3-9, CABI Publishing (2003)		
	NPL115	YAMADA, K., <i>et al.</i> , "Measurement of Glucose Uptake and Intracellular Calcium Concentration in Single, Living Pancreatic β -cells," <i>J. Biol. Chem.</i> 275:22278-22283, American Society for Biochemistry and Molecular Biology (2000)		
	NPL116	YAMAMOTO, T., <i>et al.</i> , "Over-Expression of Facilitative Glucose Transporter Genes in Human Cancer," <i>Biochem. Biophys. Res. Commun.</i> 170, 223-230, Academic Press (1990)		
	NPL117	YOSHIOKA, K., <i>et al.</i> , "Intracellular Fate of 2-NBDG, a Fluorescent Probe for Glucose Uptake Activity, in <i>Escherichia coli</i> cells," <i>Biosci. Biotech. Biochem.</i> 60:1899-1901, Japan Society for Bioscience, Biotechnology, and Agrochemistry (1996)		
	NPL118	YOSHIOKA, K., <i>et al.</i> , "A novel fluorescent derivative of glucose applicable to the assessment of glucose uptake activity of <i>Escherichia coli</i> ," <i>Biochim. Biophys. Acta</i> 1289:5-9, Elsevier Science B.V. (1996)		
	NPL119	ZHANG, M., <i>et al.</i> , "Pyropheophorbide 2-Deoxyglucosamide: A New Photosensitizer Targeting Glucose Transporters," <i>Bioconj. Chem.</i> 14:709-714, American Chemical Society (July/August 2003)		
	NPL120	ZHANG, Z., <i>et al.</i> , "Redox ratio of mitochondria as an indicator for the response of photodynamic therapy," <i>J. Biomed. Optics</i> 9:772-778, SPIE (July/August 2004)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,075
				Filing Date	December 9, 2005
				First Named Inventor	ZHENG, Gang
				Art Unit	1623
				Examiner Name	BLAND, Layla D.
Sheet	13	of	13	Attorney Docket Number	1694.0580004/JMC/CMB

NON PATENT LITERATURE DOCUMENTS

Exami ner Initial s*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL121	ZHANG, Z., <i>et al.</i> , "Metabolic Imaging of Tumors using Intrinsic and Extrinsic Fluorescent Markers," <i>Biosensors Bioelectronics</i> , 20: 643-50 (2004)	
	NPL122	ZHENG, G., <i>et al.</i> , "Synthesis, Photophysical Properties, Tumor Uptake, and Preliminary in Vivo Photosensitizing Efficacy of a Homologous Series of 3-(1'-Alkyloxy) Ethyl-3-devinaylporpurin-18-N-alkylimides with Variable Lipophilicity," <i>J. Med. Chem.</i> 44:1540-1559, American Chemical Society (2001)	
	NPL123	ZHENG, G., <i>et al.</i> , "Contrast-enhanced near-infrared (NIR) Optical Imaging for Subsurface Cancer Detection," <i>J. Porphyrins Phtalocyanines</i> , 8:1106-17 (2004)	
	NPL124	ZHENG, G., <i>et al.</i> , "Tricarbocyanine Cholesteryl Laurates Labeled LDL: New Near Infrared Fluorescent Probes (NIRFs) for Monitoring Tumors and Gene Therapy of Familial Hypercholesterolemia," <i>Bioorg. Med. Chem. Lett.</i> 12:1485-1488, Elsevier Science Ltd. (June 2002)	
	NPL125	ZHENG, G., <i>et al.</i> , "Low-Density Lipoprotein Reconstituted by Pyropheophorbide Cholesteryl Oleate as Target-Specific Photosensitizer," <i>Bioconj. Chem.</i> 13:392-396, American Chemical Society (May-June 2002)	
	NPL126	ZHENG, G., <i>et al.</i> , "Contrast-enhanced near-infrared (NIR) optical imaging for subsurface cancer detection," <i>J. Porphyrins Phtalocyanines</i> 8:1106-1117, Society of Porphyrins & Phtalocyanines (2004)	
	NPL127	ZHOU, R., <i>et al.</i> , "Enhancement of Hyperglycemia-induced Acidification of human Melanoma Xenografts by Inhibitors of Respiration and Ion Transport," <i>Acad. Radiol.</i> 8:571-582, Association Of University Radiologists (2001)	
	NPL128	ZHOU, R., <i>et al.</i> , "Intracellular Acidification of Human Melanoma Xenografts by the Respiratory Inhibitor <i>m</i> -Iodobenzylguanidine Plus Hyperglycemia: A ³¹ P Magnetic Resonance Spectroscopy Study," <i>Cancer Res.</i> 60:3532-3536, American Association for Cancer Research (2000)	
	NPL129	ZON, G., <i>et al.</i> , "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of <i>cis</i> - and <i>trans</i> -4-Hydroxycyclophosphamide with Aldophosphamide and the Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," <i>J. Med. Chem.</i> 27:466-485, American Chemical Society (1984)	

684997_2

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.